7 Killed as bus Falls Into River in J&K
President appoints Sushil Chandra as new Chief Election Commissioner of India
COVID Updates: Russia’s Sputnik V COVID-19 vaccine approved for emergency use in India
Sonia Gandhi writes to PM Modi suggesting ways to control COVID menace
FreeCurrencyRates.com

इंडियन आवाज़     13 Apr 2021 09:34:55      انڈین آواز

Covaxin 81% Effective in preventing Covid, Claims Bharat Biotech

Bharat Biotech said “analysis from the National Institute of Virology indicates that vaccine-induced antibodies can neutralise the UK variant strains and other heterologous strains”

WEB DESK

Bharat Biotech, a global leader in vaccine innovation, developing vaccines for infectious diseases, today announced the first interim analysis of its BBV152 (COVAXIN®). The whole virion inactivated COVID-19 vaccine candidate demonstrated an interim vaccine efficacy of 81% in its Phase 3 clinical trial. The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with the Indian Council of Medical Research.

The company said its initial analysis was based on 43 trial participants getting coronavirus, of whom 36 had not received the vaccine. Interim analysis also showed that severe, serious, and medically attended adverse events occurred at low levels and were balanced between vaccine and placebo groups, Bharat Biotech said. The company also said it planned further interim analysis for 87 cases and a final analysis for 130. This data has yet to be peer-reviewed.

“Today is an important milestone in vaccine discovery, for science and our fight against coronavirus. With today’s results from our Phase 3 clinical trials, we have now reported data on our COVID-19 vaccine from Phase 1, 2, and 3 trials involving around 27,000 participants.

COVAXIN® demonstrates high clinical efficacy trend against COVID-19 but also significant immunogenicity against the rapidly emerging variants,” said Dr. Krishna Ella, Chairman & Managing Director, Bharat Biotech.

BBV152 contains a whole virion inactivated SARS-CoV-2 vaccine, which is produced in Vero cells. It is stable at 2 to 8°C (refrigerated) and is shipped in a ready-to-use liquid formulation that permits distribution using existing vaccine supply chain channels. BBV152 has a 28-day open vial policy as a unique product characteristic, thus reducing vaccine wastage by approximately 10-30%.

BBV152 is based on an established manufacturing platform with a better safety profile when compared to other vaccine platforms. The inclusion of the Algel-IMDG adjuvant enhances T-cell immune responses to COVID-19, leading to long-term protection.

“I want to thank every one of the participants, who volunteered to participate in this vital clinical trial, our partners, principal investigators across 25 study sites, and our team at Bharat Biotech who dedicated their time to this vaccine discovery,” said Mrs. Suchitra Ella, Joint Managing Director, Bharat Biotech. “We could not have achieved this public-private partnership milestone without the relentless commitment of those involved.”

Interim Phase 3 Results: 81% Efficacy

The Phase 3 study enrolled 25,800 participants between 18-98 years of age, including 2,433 over the age of 60 and 4,500 with comorbidities. The primary endpoint of Phase 3 clinical trial is based on the first occurrence of PCR-confirmed symptomatic (mild, moderate, or severe) COVID-19 with onset at least 14 days after the second study vaccination in serologically negative (to SARS-CoV-2) adult participants at baseline.

The first interim analysis is based on 43 cases, of which 36 cases of COVID-19 were observed in the placebo group versus 7 cases observed in the BBV152 (COVAXIN®) group, resulting in a point estimate of vaccine efficacy of 80.6%.

The interim analysis included a preliminary review of the safety database, which showed that severe, serious, and medically attended adverse events occurred at low levels and were balanced between vaccine and placebo groups. The trial’s conduct and monitoring are as per Good Clinical Practice guidelines and have been outsourced to IQVIA.

Analysis from the National Institute of Virology indicates that vaccine-induced antibodies can neutralize the UK variant strains and other heterologous strains, which has been published in bioRxiv. https://doi.org/10.1101/2021.01.26.426986

Bharat Biotech expects to share further details of the trial results as additional data become available. An additional interim analysis is planned for 87 cases, and the final analysis is planned for 130 cases. All data from the second interim and final analyses will be shared via pre-publication servers as well as submitted to a peer-reviewed journal for publication.

More than 40 countries globally have expressed their interest in COVAXIN®. These countries are highly satisfied with the safe, inactivated vaccine technology and robust data package for safety and immunogenicity.

Leave a Reply

Your email address will not be published. Required fields are marked *

SPORTS

Hockey: Dominant India outplay Argentina 3-0 in the FIH Pro League

HPL 2020-21 - M86 - Men ARG v IND 11/4/21,Argentina, Capital Federal Location: CENARD PHOTO: Rodrigo Jarami ...

Kiren Rijiju inaugurates KICE in Rowing in Srinagar

AMN Union sports minister Kiren Rijiju inaugurated the Khelo India Centre of Excellence in Rowing in Srinag ...

خبرنامہ

قرآن کریم اور اس کی 26 آیتیں: صرف ترجمہ نہیں ،تفسیر بھی پڑھیں

جو لوگ مذہب کی بنیاد پر اسلام میں غیر مسلموں کے قتل کو جائز سم ...

بنگلہ دیش کے قومی دن کے پروگرام کے موقع پر وزیر اعظم کے خطاب کا متن

ئی دلّی ، 26 مارچ / نوموشکار ! حضراتِ گرامی  ، بنگلہ دی ...

چھتیس گڑھ میں ماؤنوازوں کے حملے میں پانچ سکیورٹی اہلکارہلاک اور 12 زخمی ہوگئے۔

یہ واقعہ بستر خطے کے نرائن پور ضلعے میں آج شام اُس وقتپ آیا ج ...

TECH AWAAZ

Abu Dhabi Digital signs partnership agreement with Hewlett Packard Enterprise

WEB DESK The Abu Dhabi Digital Authority (ADDA)has signed a partnership agreement with Hewlett Packard Ente ...

Indian Army develops messaging application ‘Secure Application for Internet’

file phot AMN Indian Army has developed a simple messaging application named the Secure Application for ...

MARQUEE

It is time to relish ‘Sadabahar’ mango

By Andalib Akhter A farmer from Kota, Rajasthan has developed an innovative mango variety called ‘Sadabah ...

Indian Army Closes Down Military Farms

WEB DESK After 132 years of glorious service to the nation, curtains were drawn on Military Farms. These Fa ...

MEDIA

There is no proposal to appoint a regulator for social media: Govt

AMN / WEB DESK The government has said that there is no proposal to appoint a regulator for social media. I ...

Centre approves financial assistance of Rs 5 lakh in death cases of journalists

Staff Reporter / NEW DELHI The Government today said that it has approved financial assistance of 5 lakh ru ...

@Powered By: Logicsart

The Indian Awaaz